Sanofi targets ground-breaking therapies with a new R&D strategy

Going above and beyond

What will be Sanofi's R&D goals in the coming years? Reed already has concrete plans in mind - the company will expect 8 major submissions in 2022 and 20 more in the next 3 to 5 years in the fields of immunology, oncology, rare blood disorders and vaccines.

"While I take pride in all our accomplishments as an organization, the progress we have made in immunology & inflammation (I&I) is particularly gratifying for me. Our I&I portfolio four years ago was behind the curve compared to our peers. Today, it is arguably one of the most vibrant elements of Sanofi's pipeline with 15 products in development and our flagship medicine growing rapidly in numbers of patients treated. Moreover, our focus on immunoscience at Sanofi has benefited not only the I&I therapeutic area, but it has also served as the foundation for driving progress across our other therapeutic areas, including neurology, hematology, oncology and vaccines."

" Reviewing our success to-date, it's clear that Sanofi is committed to delivering best-in-class innovation, playing to our strengths, and making the necessary deliberate choices about resource allocation to focus our investments on what matters most for patients. Every day, we have the duty to turn great science into new opportunities for patients, and we will continue to do so in 2022."

Diseases are very close to us, and Sanofi is telling us that medical miracles are also very close to us with each of its attempts for scientific breakthroughs.

For pharmaceutical companies, being R&D-driven and placing clinical value first is not just business logic, but a kind of reverence for life, and also the true meaning behind Sanofi's motto of "Chasing the miracles of science to improve people's life".

As Reed said, "News headlines can make scientific advances appear like overnight successes rather than the evolution of hundreds of small discoveries made throughout decades." Sanofi is fully committed to devoting time, resources, and commitment that will be needed in the pursuit of its mission for patients.